As anticipated in the title, this contribution is basically divided into two, strictly connected, parts. The first is a personal overview of the ruthenium drug candidate NAMI-A, almost 30 years after its synthesis and the discovery of its unprecedented antimetastatic properties in animal models at nontoxic dosages. The sections relating to the chemical and biological behavior of the complex, and the hypotheses on its mechanism(s) of action, are kept to a minimum, whereas more space is devoted to discussion of the results of the clinical investigations. The second part deals in detail with a number of undemonstrated misconceptions (or myths) that, over the years, have thrived around NAMI-A and other ruthenium drug candidates, thus negatively affecting the whole field of Ru anticancer drugs.

Thirty Years of the Drug Candidate NAMI-A and the Myths in the Field of Ruthenium Anticancer Compounds: A Personal Perspective

ALESSIO, ENZO
2016

Abstract

As anticipated in the title, this contribution is basically divided into two, strictly connected, parts. The first is a personal overview of the ruthenium drug candidate NAMI-A, almost 30 years after its synthesis and the discovery of its unprecedented antimetastatic properties in animal models at nontoxic dosages. The sections relating to the chemical and biological behavior of the complex, and the hypotheses on its mechanism(s) of action, are kept to a minimum, whereas more space is devoted to discussion of the results of the clinical investigations. The second part deals in detail with a number of undemonstrated misconceptions (or myths) that, over the years, have thrived around NAMI-A and other ruthenium drug candidates, thus negatively affecting the whole field of Ru anticancer drugs.
http://dx.doi.org/10.1002/ejic.201600986
File in questo prodotto:
File Dimensione Formato  
EurJIC 2017, 1549-1560 Review.pdf

non disponibili

Descrizione: Articolo completo
Tipologia: Documento in Versione Editoriale
Licenza: Digital Rights Management non definito
Dimensione 1.67 MB
Formato Adobe PDF
1.67 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
EurJIC 2017 review versione post-print.pdf

embargo fino al 28/09/2017

Descrizione: Versione post-print dell'autore
Tipologia: Bozza finale post-referaggio (post-print)
Licenza: Digital Rights Management non definito
Dimensione 921.88 kB
Formato Adobe PDF
921.88 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11368/2898222
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 259
  • ???jsp.display-item.citation.isi??? 263
social impact